ABCB1 and urinary bladder cancer: In urinary bladder cancer, the effects of the ABCB1 rs1128503 polymorphism on temsirolimus and its active metabolite sirolimus following administration were associated with an increased drug concentration (p = 0.037) and a prolonged sirolimus half-life (p = 0.010).